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ABSTRACT
Background: Cardiotoxicity is a known complication and one of the most adverse effects from the use of
conventional treatments such as anthracyclines and trastuzumab in breast cancer (BC) care. This phenomenon has
been associated with the restriction of therapeutic options and the increase of cardiovascular complications, which
may compromise the survival of patients. Implementation of preventive strategies is an important approach for the
management of this issue. Physical exercise has been proposed as a non-pharmacological strategy to counteracting
cardiotoxicity. The aim of this protocol is to describe the rationale and methods for a systematic review of
published randomized controlled trials (RCTs) that have analysed the effects of physical exercise on outcomes of
cardiac (dys)function in women with BC undergoing neoadjuvant or adjuvant treatment containing anthracyclines
and/or trastuzumab.
Methods and analysis: This is a protocol for a systematic review reported according to the PRISMA-P 2015 checklist.
Randomized controlled trials (RCTs) will be included. The literature will be screened on MEDLINE, EMBASE, the
Cochrane Central Register of Controlled Trials, ISI Web of Science and Scopus. The risk of bias of the included RCTs will
be assessed using the Cochrane Collaboration’s tool. The primary outcomes will be systolic function (left ventricular
ejection fraction), diastolic function (E/A’ ratio, deceleration time of early left ventricular filling, isovolumetric relaxation
time, E/E’ septal and lateral ratio) and myocardial deformation imaging outcomes (strain and strain rate [measured in
longitudinal, radial, or circumferential directions]). Secondary outcomes will be cardiac biomarkers (troponin I or T, high-
sensitivity troponin I or T, brain natriuretic peptide, amino terminal of B-type natriuretic peptide). Data will be
descriptively reported, and quantitative synthesis will also be considered if the included studies are sufficiently
homogenous.
Discussion: This systematic review will help to understand the effectiveness of physical exercise on counteracting
cardiotoxicity related to anticancer therapies in women with BC.
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BACKGROUND
Breast cancer (BC) is the most diagnosed malignancy and
the major cause of cancer-related death in the female
gender [1]. Over the past two decades, due to preventive
actions, early screening and advances in anticancer thera-
pies, the BC management has been marked by a notable
progress reflected by the improvement in survival rates
[2]. However, despite the optimistic prospects in the fight
against BC, survivorship is often marked by several treat-
ment-related side effects and poor quality of life [3,
4]. Notably, cardiotoxicity has been recognized as a
serious issue in clinical practice, restricting treatment
options and contributing to morbidity and mortality
among BC patients [5, 6].
Cardiac dysfunction, which involves direct effects of
the treatment on heart function and structure [7], is a
well-established side effect from the use of conven-
tional cardiotoxic drugs such as anthracyclines (the
cornerstone of BC chemotherapy) and trastuzumab
(the standard of care for the treatment of human epi-
dermal growth factor receptor 2 (HER2)-positive) in
BC treatment [8]. Anthracycline-induced cardiotoxi-
city is mostly influenced by cumulative dose, leading
to an irreversible cardiac damage (type I cardiotoxi-
city) [9]. The anthracycline-related cardiac effects are
commonly manifested by asymptomatic or symptom-
atic left ventricular dysfunction leading to heart fail-
ure, myocardial ischemia, arrhythmias, hypertension,
myocarditis, pericarditis and thromboembolism [10].
On the other hand, trastuzumab-related cardiotoxicity
is not dose-dependent and is often reversible (type II
cardiotoxicity) after treatment discontinuation [11].
Nevertheless, the elevated incidence of cardiac dys-
function in patients treated with trastuzumab after
anthracyclines is a growing concern [12].
According to the American Society of Echocardiog-
raphy and the European Association of Cardiovascular
Imaging, cardiotoxicity is defined by a decrease in left
ventricular ejection fraction (LVEF) of > 10% to a value
of < 53% [13]. Currently, serial determination of LVEF is
the standard marker for reporting cardiotoxicity related
to anticancer therapies [7]. However, the determination
of LVEF has substantial limitations and is considered a
poor sensitivity parameter to detect cardiotoxicity at an
early stage [14]. As such, an integrated approach that in-
cludes the assessment of echocardiographic parameters
(diastolic function and myocardial deformation imaging)
and biomarkers of cardiac injury has been recommended
for a better monitoring of cardiac (dys)function [13, 15].
Besides the importance of screening, the implementation
of preventive strategies that optimize cardiovascular care
in patients with BC treated with cardiotoxic agents is
also an important component to avoid this issue, but
currently, they are limited [16].
Physical exercise is recognized as a viable non-
pharmacological approach for the management of sev-
eral cardiovascular risk factors [17, 18] and as a safe and
effective supportive care for cancer survivors [19]. Evi-
dence from meta-analysis highlights its beneficial effects
on physiological and psychological outcomes, during
[20] or after treatment [21], as well as its important role
in surveillance and disease recurrence [22]. Furthermore,
exercise has also been proposed as a promising strategy
to prevent cardiotoxicity related to anticancer therapies
[7, 23]. There are several review studies that analysed
and described the potential protection mechanisms of
physical exercise against cardiotoxicity, but most of
these have reported data from animal studies [24–27].
To the best of our knowledge, no systematic review has
summarized the effects of physical exercise on cardiac
(dys)function induced by neoadjuvant or adjuvant treat-
ment containing anthracyclines and/or trastuzumab in
adult women with BC.
Therefore, this systematic review will aim to analyse
the existing evidence regarding the role of physical exer-
cise on outcomes of cardiac (dys)function in intervention
studies that involved women with BC who were under-
going neoadjuvant or adjuvant treatment containing
anthracyclines and/or trastuzumab.
Methods and analysis
Study design
This is a protocol for a systematic review which is
registered in the international Prospective Register of
Systematic Reviews (PROSPERO; registration number:
CRD42018096060) and has been developed in accord-
ance with the Preferred Reporting Items for System-
atic Review and Meta-Analysis Protocols (PRISMA-P)
[28, 29] (available in Additional file 1).
Patient and public involvement
No patients will be involved in this study.
Eligibility criteria
We will include studies that meet the following criteria:
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Study type Published randomized controlled trials
(RCTs) will be eligible. Due to funding restraints, we will
include studies in English, French, Germany, Portuguese
and Spanish language.
Participants Studies that involving adult women (> 18 years
old) with BC, who were undergoing in a neoadjuvant or
adjuvant treatment containing anthracyclines and/or
trastuzumab and performed concurrently a physical
exercise intervention, were included. Studies which
involved other cancer types beyond BC will be excluded.
Intervention Studies that involved aerobic training (any
exercise form that uses large muscle groups which pre-
dominately stresses the cardiovascular system, such as
walking, jogging, cycling) and resistance training (any
exercise form that requires a muscle or a muscle group
to work against external resistance which predominately
stresses the musculoskeletal system, such as squats,
chest press), according to the American College of
Sports Medicine [30], isolated or in combination, will be
included. Trials will not be considered if:
 Yoga, tai chi chuan, qigong or pilates was defined as
physical intervention.
 The physical exercise intervention group performed
other supportive care (e.g. dietary plan).
Comparator(s) Comparators will include non-exercise
group (i.e. waiting list, control or placebo).
Outcomes Studies that report the absolute and/or per-
centage change from baseline to the end of the interven-
tion and/or at follow-up, on at least one of the following
outcomes, will be considered:
 Primary outcomes: resting LVEF
 Secondary outcomes: resting parameters of diastolic
function [E/A’ ratio; deceleration time of early left
ventricular filling (DT); isovolumetric relaxation
time (IVRT); E/E’ lateral and E/E’ septal]; resting
parameters of myocardial deformation imaging
(strain and strain rate); cardiac biomarkers
(troponin I or T; high-sensitivity troponin I or T;
brain natriuretic peptide; amino terminal of
B-type natriuretic peptide)
Search methodology for identification of studies
Electronic databases Literature search will be per-
formed in the following electronic bibliographic data-
bases: MEDLINE (via PubMed), EMBASE (Via embase.
com), the Cochrane Central Register of Controlled Trials
(CENTRAL), ISI Web of Science and Scopus. Moreover,
clinical trial registers such as ClinicalTrials.gov (https://
ClinicalTrials.gov), World Health Organization (WHO)
trials portal (www.who.int/ictrp/en/) and International
Clinical Trials Registry Platform registry (http://www.
isrctn.com) will be also scanned to identify ongoing and/
or protocols trials. Furthermore, the references of the in-
cluded manuscripts and relevant reviews will be checked.
No restriction will be applied regarding the year of pub-
lication and the language of the study. This researching
process will be independently conducted by two review
authors (PA and DE).
Search terms and keywords The specific search strat-
egies were created through a consensus between all the
authors and will include the following four concepts and
their related terms: (1) condiction (i.e. breast cancer), (2)
cancer treatment (i.e. anthracyclines and trastuzumab), (3)
exercise (i.e. aerobic exercise and resistance exercise) and
(4) study type (i.e. controlled trial). It will be used as text
terms and indexing terms from the thesaurus of the
databases (i.e. Medical Subject Headings (MeSH) for
MEDLINE and CENTRAL and Emtree for EMBASE) and
Boolean operators. The search strategy for MEDLINE is
outlined at Table 1 and will be adapted for the further
databases. This researching process will be independently
conducted by two review authors (PA and DE).
Data management
Studies selection Screening search results will be entered
into the latest version of EndNote (Clarivate Analytics)
and duplicates will be removed. These procedures will be
independently conducted by two review authors (PA and
DE). After this, to test the eligibility criteria, the same two
review authors will independently evaluate the title and
abstract of the studies. The manuscripts that appear to
meet the eligibility criteria will be recorded using an Excel
predesigned criterion data collection form. Then, the same
two review authors (PA and DE) will meet in person and
perform a non-blind full-text screening to take a final in-
clusion decision. Reasons for exclusion will be recorded.
Possible disagreements will be resolved by discussion or, if
necessary, by the judgement of a third author (AAl).
Whenever required, the study’s corresponding authors will
be contacted to provide possible ambiguous or lack of
necessary information.
Data extraction
Two review authors (CN and VA) will independently
perform data extraction using a Microsoft Office Excel
version 2016 (Microsoft Corporation, Redmond, WA,
USA) predesigned criterion data collection form. The
following data will be collected:
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 Study characteristics: primary aim, authors, year of
publication, journal name, country and sample size
 Participant characteristics: mean age, disease stage
and treatment scheme
 Intervention characteristics: exercise type, intensity,
frequency, time, supervision, location and, if
provided, we will also highlight safety and feasibility
 Comparison details: placebo or control group
 Interested study outcomes: data of the study
outcomes (effect size, 95% CI, standard mean
deviation) and its measuring methods
When ambiguous or clarification of data is required,
the study’s corresponding authors will be contacted (via
email). Possible disagreements during this process will
be resolved by consensus or, if necessary, by a third re-
view author’s judgement (AAl).
Assessment risk of bias of the included studies
Two review authors (AJ and AA) will independently as-
sess and score the methodological quality of the in-
cluded trials using the Cochrane Collaboration’s tool for
assessing risk of bias, according to the following do-
mains: random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective
reporting and other potential sources of bias [31]. The
level of risk of bias will be determined for each domain:
(1) high risk, (2) unclear risk or (3) low risk. Possible dis-
agreements shall be resolved by discussion and, if neces-
sary, by consulting a third review author (AAl). We will
use the Grades of Recommendation, Assessment, Devel-
opment and Evaluation (GRADE) approach to assess the
quality of the evidence across studies [32].
Heterogeneity assessment
Statistical heterogeneity will be tested by the χ2 test and
quantified by the I2 statistic. Heterogeneity will be
assumed if we verified a p value of < 0.1 for χ2 and I2 of
≥ 50% [33]. We will perform sensitivity analyses stratified
according to the risk of bias.
Data synthesis
Data will be managed using the Review Manager soft-
ware version 5.3 (Nordic Cochrane Centre, the Cochrane
Collaboration, Copenhagen, Denmark). The characteris-
tics and findings extracted from the included studies will
be exposed in a descriptive way, through tables, and
complemented with a synthetic narrative which explores
the relationship between the trials. If heterogeneity is
found in most studies, regarding design and comparator,
random effects model meta-analyses will be performed.
For continuous outcomes, we planned to estimate stan-
dardized mean difference (SMD) with confidence inter-
val of 95% (CI 95%). When standard deviations are not
available, they will be calculated from standard errors,
CI or t values for both groups for each study included.
The magnitude of the effect size will be reported accord-
ing to Cohen’s classification with the following: small
(SMD = 0.2–0.5), moderate (SMD = 0.5–0.8) and large
(SMD > 0.8) [34].
Assessment of reporting bias
We will examine funnel plots corresponding to meta-
analysis of the primary outcomes to assess the potential
for small-study effects such as publication bias if we
include more than 10 studies in an analysis.
Subgroups analyses
If sufficient data is available, we will perform subgroup
analyses according to the following:
 Intervention type (aerobic or resistance,
concomitant or isolated)
 Exercise intensity (light, moderate, vigorous)
 Treatment scheme (including anthracyclines or
trastuzumab, concomitant or isolated)
Ethics and dissemination
Ethics approval is not required because this is a protocol
for a systematic review not involving personal data or the
exercise of any intervention in patients. The findings of
this study will be submitted to a peer-reviewed journal for
publication, will be presented at relevant conferences and
will be also part of the main author’s PhD thesis.
Table 1 Search strategy for MEDLINE (via PubMed)
Concept Related terms
#1 condition ((breast neoplasms[MeSH]) OR ((breast[MeSH] OR breast diseases[MeSH]) AND neoplasms[MeSH])) OR ((Breast[tiab] OR
mammary[tiab]) AND cancer*[tiab] OR carcinoma*[tiab] OR tumour*[tiab] OR malignant*[tiab] OR neoplasm*[tiab]))
#2 cancer
treatment
((chemotherapy[MeSH]) OR anthracycline[MeSH]) OR trastuzumab[MeSH]) OR Antibodies, Monoclonal, Humanized[MeSH]) OR
(chemotherap*[tiab] OR anthracycline*[tiab] OR trastuzumab[tiab] OR herceptin[tiab]))
#3 exercise ((Exercise training[MeSH]) OR Resistance training[MeSH]) OR Exercise therapy[MeSH]) OR ((Exercise[tiab] OR training[tiab] OR
sport*[tiab]) AND aerobic*[tiab] OR resistance*[tiab] OR strength*[tiab] OR weight [tiab] OR endurance*[tiab]))
#4 study type ((randomized controlled trial[pt]) OR controlled clinical trial[pt]) OR (randomized[tiab] OR randomly[tiab] OR trial[tiab]))
#1 AND #2 AND #3 AND #4
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Discussion
The notable progress in the care of BC has led to a
marked improvement in survival rates [2]. Despite the
optimistic prospects in the fight against BC, these pa-
tients face several treatment-related side effects [3, 4].
Cardiac dysfunction has been recognized as a major
concern from the use of conventional cardiotoxic
drugs [6], such as anthracyclines and trastuzumab,
which can occur either during treatment or after it [7].
The implementation of preventive strategies to
optimize and balance cardiac health is needed. Physical
exercise has been emerging as a potential approach for
counteracting cardiotoxicity related to anticancer ther-
apies [7, 23]. Previous review studies have analysed
and described the potential protection mechanisms of
physical exercise against cardiotoxicity [24–27], but
most of these have reported data from animal studies.
Until now, no systematic review has summarized the
effects of physical exercise on cardiac (dys)function
induced by neoadjuvant or adjuvant treatment contain-
ing anthracyclines and/or trastuzumab in adult women
with BC.
Limitations
We anticipate some limitations. There may be a risk of
bias as we only include published articles. Moreover, this
systematic review may be limited by the lack of studies
and significant heterogeneity among them.
Conclusion
In this systematic review, we will conduct a comprehen-
sive and rigorous research to summarize and clarify the
potential cardioprotective effect of physical exercise at
mitigating cardiotoxicity in women with BC undergoing
neoadjuvant or adjuvant treatment containing anthracy-
clines and/or trastuzumab. We expect to present solid
findings in this work that it may facilitate the integration
of future policies which aim at balancing the negative
cardiac effects related to the use of cardiotoxic drugs in
the care management of BC, making decisions regarding
the practice of exercise.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-019-1154-x.
Additional file 1. PRISMA-P 2015 Checklist.
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